Therabest

Therabest, a cell therapy company, has developed TB-100, an iPSC-derived NK cell therapy, which, in combination with Glycotope's tumor-targeting immunocytokine GT-00A x IL15, may offer a new approach to improving treatment efficacy for triple-negative breast cancer in the future.